RE: StockBox podcast feat. IMM discussion17 Feb 2025 08:33
He is perhaps inferring it from the two mentions of Lupus as the lead program.
"effective in a number of auto-immune diseases including our lead program, for lupus."
"Importantly for our autoimmune therapy P140, especially for our lead indication in SLE (Lupus)"
However, I detect much more emphasis on P140 as a platform, perhaps after the breakthough findings. Sk perhaps that will need change to P3 plans.
"Additional funding at this pivotal time will allow the management to invest further into the P140 platform."
"strengthen the Company's negotiating position in ongoing licensing negotiations"
"Being able to apply this new funding to the P140 program will deliver quicker results and also be a major contributor to regular positive news flow and program updates which will have a major impact to drive a positive upward movement in the share price"
I suspect IMM are aiming big here.
This is the year for delivery says the CEO. Transformatiomal year.
Now you either believe that or your don't. If you beleive it, now is the time to be buying, before whatever newsflow they have appears.
All my opinion, of course.